The Toxicity of Doxorubicin with Nanotransporters

Authors: I. Blazkova, A. Moulick, V. Milosavljevic, P. Kopel, M. Vaculovicova, V. Adam, R. Kizek

Abstract:

Doxorubicin (DOX) is an anthracycline drug used to treat many cancer diseases. Similarly to other cytostatic drugs, DOX has serious side effects; the biggest obstacle is the cardiotoxicity. With the aim of lowering the negative side effects and to target the DOX into the tumor tissue, the different nanoparticles (NPs) are studied. The aim of this work was to synthetized different NPs and conjugated them with DOX and determine the binding capacity of the NPs. For this experiment, carbon nanotubes (CNTs), graphene oxide (GO), fullerene (FUL) and liposomes (LIP) were used. The highest binding capacity was observed in GO (85%). Subsequently the toxicity of NPs and NPs-DOX conjugates was analyzed in in vivo system (chicken embryos). Some NPs (GO) can increase the toxicity of DOX, whereas other NPs (LIP, CNTs) decrease DOX toxicity.

Keywords: Chicken embryos, Doxorubicin, Nanotransporters, Toxicity

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1107265

References:

[1] Chen, Y. et al. Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. International Journal of Nanomedicine, 2011, vol. 6, pp. 2321-2326. ISSN 1178- 2013.
[2] Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, vol. 2, no. 12, pp. 751-760. ISSN 1748- 3387.
[3] Du, J. Z. et al. Tailor-Made Dual pH-Sensitive Polymer-Doxorubicin Nanoparticles for Efficient Anticancer Drug Delivery. Journal of the American Chemical Society, 2011, vol. 133, no. 44, pp. 17560-17563. ISSN 0002-7863.
[4] li, Y. L. et al. Reversibly Stabilized Multifunctional Dextran Nanoparticles Efficiently Deliver Doxorubicin into the Nuclei of Cancer Cells. Angewandte Chemie-International Edition, 2009, vol. 48, no. 52, pp. 9914-9918. ISSN 1433-7851.
[5] Brigger, I. et al. Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 2012, vol. 64, pp. 24-36. ISSN 0169- 409X.
[6] Malam, Y. et al. Current Trends in the Application of Nanoparticles in Drug Delivery. Current Medicinal Chemistry, 2011, vol. 18, no. 7, pp. 1067-1078. ISSN 0929-8673.
[7] Ayen, W. Y. a KUMAR, N. In vivo Evaluation of Doxorubicin-Loaded (PEG)(3)-PLA Nanopolymersomes (PolyDoxSome) Using DMBAInduced Mammary Carcinoma Rat Model and Comparison with Marketed LipoDox (TM). Pharmaceutical Research, 2012, vol. 29, no. 9, pp. 2522-2533. ISSN 0724-8741.
[8] Chen, Y.-C. et al. Non-metallic nanomaterials in cancer theranostics: a review of silica- and carbon-based drug delivery systems. Science and Technology of Advanced Materials, 2013, vol. 14, no. 4. ISSN 1468- 6996.
[9] Lim, D. J. et al. Carbon-based drug delivery carriers for cancer therapy. Archives of Pharmacal Research, 2014, vol. 37, no. 1, pp. 43-52. ISSN 0253-6269.
[10] Ali-Boucetta, H. et al. Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chemical Communications, 2008, no. 4, pp. 459-461. ISSN 1359-7345.
[11] Novoselov, K. S. et al. A roadmap for graphene. Nature, 2012, vol. 490, no. 7419, pp. 192-200. ISSN 0028-0836.
[12] Huang, X. et al. Graphene-based composites. Chemical Society Reviews, 2012, vol. 41, no. 2, pp. 666-686. ISSN 0306-0012.
[13] Dellinger, A. et al. Application of fullerenes in nanomedicine: an update. Nanomedicine, 2013, vol. 8, no. 7, pp. 1191-1208. ISSN 1743-5889.
[14] Chen, Z. et al. Applications of functionalized fullerenes in tumor theranostics. Theranostics, 2012, vol. 2, no. 3, pp. 238-250. ISSN 1838- 7640.
[15] Swenson, C. E. et al. Liposome technology and the development of Myocet (TM) (liposomal doxorubicin citrate). Breast, 2001, vol. 10, pp. 1-7. ISSN 0960-9776.
[16] Barenholz, Y. a Peer, D. Liposomes and other assemblies as drugs and nano-drugs: From basic and translational research to the clinics preface. Journal of Controlled Release, 2012, vol. 160, no. 2, pp. 115-116. ISSN 0168-3659.
[17] Lowery, A. et al. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. Journal of Controlled Release, 2011, vol. 150, no. 1, pp. 117- 124. ISSN 0168-3659.
[18] Batist, G. et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of Clinical Oncology, 2001, vol. 19, no. 5, pp. 1444-1454. ISSN 0732-183X.
[19] Gyoengyoesi, M. et al. Comparison of the cardiotoxic effect of doxorubicin and liposome-encapsulation of doxorubicin under experimental condition. Annals of Oncology, 2014, vol. 25. ISSN 0923- 7534.
[20] Hummers, W. S. a Offeman, R. E. Preparation of Graphitic Oxide. Journal of the American Chemical Society, 1958, vol. 80, no. 6, pp. 1339-1339. ISSN 0002-7863.
[21] Blazkova, I. et al. Study of fluorescence of doxorubicin in muscle tissue using highly sensitive fluorescence sensing. Chem. Sensors, 2014, vol. 4, no. 9, pp. 1-6. ISSN 2231-6035.
[22] Kensova, R. et al. The Effect of Cadmium Ions and Cadmium Nanoparticles on Chicken Embryos and Evaluation of Organ Accumulation. International Journal of Electrochemical Science, 2015, vol. 10, no. 4, pp. 3623-3634. ISSN 1452-3981.
[23] Konecna, R. et al. Doxorubicin encapsulation investigated by capillary electrophoresis with laser-induced fluorescence detection. Chromatographia, 2014, vol. 77, no. 21-22, pp. 1469-1476. ISSN 0009- 5893.
[24] Kominkova, M. et al. Study of functional qualities of different types of tailored liposomes with encapsulated doxorubicin using electrochemical and optical methods. International Journal of Electrochemical Science, 2014, vol. 9, no. 6, pp. 2993-3007. ISSN 1452-3981.
[25] Blazkova, I. et al. Apoferritin modified magnetic particles as doxorubicin carriers for anticancer drug delivery. Int. J. Mol. Sci., 2013, vol. 14, no. 7, pp. 13391-13402. ISSN 1422-0067.
[26] Blazkova, I. et al. Fullerene as a transporter for doxorubicin investigated by analytical methods and in vivo imaging. Electrophoresis, 2014, vol. 35, no. 7, pp. 1040-1049. ISSN 0173-0835.
[27] Patel, K. J. et al. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemotherapy and Pharmacology, 2013, vol. 72, no. 1, pp. 127-138. ISSN 0344-5704.
[28] Bouccara, S. et al. Enhancing fluorescence in vivo imaging using inorganic nanoprobes. Current Opinion in Biotechnology, 2015, vol. 34, pp. 65-72. ISSN 0958-1669.